Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.33 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.32 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.32 |
| ▸ | PPARD | Q03181 | 2/20 | 0.32 |
| ▸ | PPARA | Q07869 | 1/20 | 0.32 |
| ▸ | GLS | O94925 | 1/20 | 0.31 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.31 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.31 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1634152 | 0.92 | PPARG (0.43) | PPARGSCN9ATAAR1PPARDGLS | |
| SCHEMBL6034696 | 0.92 | PPARG (0.32) | PPARG | |
| SCHEMBL6035639 | 0.91 | PTGER1 (0.33) | PPARGPTGER4PTGER3PTGER2 | |
| SCHEMBL1634394 | 0.88 | PPARG (0.40) | PPARGSCN9APPARDPPARA | |
| SCHEMBL6035415 | 0.87 | PPARG (0.40) | PPARGSCN9APAX8TAAR1PPARD | |
| SCHEMBL1633509 | 0.85 | PPARG (0.33) | PPARGPPARD | |
| SCHEMBL6035235 | 0.84 | PPARG (0.44) | PPARGSCN9APAX8TAAR1PPARD | |
| SCHEMBL1633621 | 0.83 | PPARG (0.48) | PPARGSCN9ATAAR1 | |
| SCHEMBL1634795 | 0.83 | PPARG (0.42) | PPARGSCN9ATAAR1PTGER4PTGER3 | |
| SCHEMBL6035887 | 0.82 | PPARG (0.43) | PPARGSCN9ATAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060148858-A1 | 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060148858-A1 | 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity | GPR119, SLC5A1, CYP4B1 | PPARG 1037/4885SCN9A 2020/4885PAX8 2629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.